225,082 Shares of Aurinia Pharmaceuticals Inc $AUPH Bought by Bank of America Corp DE

Key Points

• Bank of America acquired 225,082 shares of Aurinia Pharmaceuticals in the second quarter, worth approximately $3.82 million and representing 0.17% of the company.
• Several other institutional investors also initiated positions, bringing institutional and hedge-fund ownership of Aurinia to 36.83%.
• Aurinia reported quarterly EPS of $0.28, exceeding the $0.24 consensus estimate, while revenue of $58.57 million fell short of the $80.45 million forecast. Analysts maintain a “Moderate Buy” consensus with an average price target of $17.67.

Bank of America Corp DE bought a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 225,082 shares of the biotechnology company's stock, valued at approximately $3,820,000. Bank of America Corp DE owned 0.17% of Aurinia Pharmaceuticals at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Freestone Grove Partners LP acquired a new position in shares of Aurinia Pharmaceuticals during the second quarter worth approximately $979,000. Man Group plc acquired a new stake in Aurinia Pharmaceuticals in the 2nd quarter valued at $1,424,000. Jupiter Topco LLC bought a new stake in Aurinia Pharmaceuticals during the 2nd quarter valued at $10,219,000. PDT Partners LLC bought a new stake in Aurinia Pharmaceuticals during the 2nd quarter valued at $4,505,000. Finally, Legal & General Group Plc bought a new stake in Aurinia Pharmaceuticals during the 2nd quarter valued at $1,747,000. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Price Performance

AUPH opened at $16.42 on Wednesday. Aurinia Pharmaceuticals Inc has a 1 year low of $10.90 and a 1 year high of $19.25. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.42 and a quick ratio of 4.97. The company has a market capitalization of $2.18 billion, a price-to-earnings ratio of 7.17 and a beta of 1.40. The firm's fifty day moving average price is $15.97 and its two-hundred day moving average price is $15.80.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its earnings results on Thursday, August 6th. The biotechnology company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.24 by $0.04. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%. The firm had revenue of $58.57 million for the quarter, compared to analysts' expectations of $80.45 million. As a group, analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.9 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

AUPH has been the topic of a number of recent research reports. Weiss Ratings raised shares of Aurinia Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, August 26th. Royal Bank Of Canada boosted their target price on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a "sector perform" rating in a research report on Friday, August 7th. Zacks Research lowered shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 21st. Bloom Burton raised shares of Aurinia Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 20th. Finally, Wall Street Zen downgraded Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $17.67.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc NASDAQ: AUPH is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company's primary product is Lupkynis (voclosporin), an oral calcineurin inhibitor approved for use in combination with background immunosuppressive therapy to treat adult patients with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Lupkynis is designed to help control the underlying immune response associated with lupus nephritis and reduce the risk of progressive kidney damage.

Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.